Leila J. Williams

3.1k total citations
17 papers, 240 citations indexed

About

Leila J. Williams is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Leila J. Williams has authored 17 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Immunology. Recurrent topics in Leila J. Williams's work include CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CRISPR and Genetic Engineering (4 papers). Leila J. Williams is often cited by papers focused on CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and CRISPR and Genetic Engineering (4 papers). Leila J. Williams collaborates with scholars based in United States, India and France. Leila J. Williams's co-authors include Weiyi Peng, Courtney W. Hudgens, Grant M. Fischer, Jennifer L. McQuade, Philip L. Lorenzi, Lin Tan, Andrew L. MacKinnon, Jason Roszik, Barbara Knighton and Y.N. Vashisht Gopal and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Leila J. Williams

16 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leila J. Williams United States	6	99	99	75	74	49	17	240
Hongying Zheng China	8	111 1.1×	119 1.2×	48 0.6×	66 0.9×	102 2.1×	23	310
Sihui Yu China	8	153 1.5×	47 0.5×	84 1.1×	81 1.1×	36 0.7×	12	255
Fanjun Cheng China	8	111 1.1×	120 1.2×	77 1.0×	37 0.5×	13 0.3×	25	241
Jessica Vick United States	6	187 1.9×	69 0.7×	26 0.3×	147 2.0×	121 2.5×	7	323
Triantafyllia Ntouroupi Greece	8	47 0.5×	97 1.0×	16 0.2×	57 0.8×	25 0.5×	9	240
Jamie A. Saxon United States	9	130 1.3×	136 1.4×	137 1.8×	47 0.6×	99 2.0×	12	342
Zahraa Rahal United States	8	119 1.2×	89 0.9×	31 0.4×	74 1.0×	71 1.4×	14	245
Rita Balsano Italy	9	87 0.9×	90 0.9×	26 0.3×	51 0.7×	32 0.7×	20	192
Min K. Tsai United States	8	138 1.4×	55 0.6×	36 0.5×	48 0.6×	31 0.6×	11	221

Countries citing papers authored by Leila J. Williams

Since Specialization

Citations

This map shows the geographic impact of Leila J. Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leila J. Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leila J. Williams more than expected).

Fields of papers citing papers by Leila J. Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leila J. Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leila J. Williams. The network helps show where Leila J. Williams may publish in the future.

Co-authorship network of co-authors of Leila J. Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Leila J. Williams. A scholar is included among the top collaborators of Leila J. Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leila J. Williams. Leila J. Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Fedoriw, Andrew, Leilei Shi, Shane W. O’Brien, et al.. (2022). Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses. Cancer Immunology Research. 10(4). 420–436. 26 indexed citations

Tao, Xuguang, Robert A. Lavin, Nicholas F. Tsourmas, et al.. (2022). Early Drug Prescription Patterns as Predictors of Final Workers Compensation Claim Costs and Closure. Journal of Occupational and Environmental Medicine. 64(12). 1046–1052. 1 indexed citations

Wong, Karrie, Leila J. Williams, Nicholas Constant, et al.. (2022). 297 Manufacture of KSQ-001, a CRISPR/Cas9-engineered TIL (eTIL) therapy, for the treatment of head and neck squamous cell carcinoma. Regular and Young Investigator Award Abstracts. A312–A312.

Lin, Sharon, Leila J. Williams, Hugh Gannon, et al.. (2022). 255 ExPRESS^TM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTIL^TM product. Regular and Young Investigator Award Abstracts. A270–A270. 1 indexed citations

Lavin, Robert A., et al.. (2021). Trends in the Utilization and Dose of Gabapentinoids in Combination With Opioids in an Injured Worker Population Between 2008 and 2018. Journal of Occupational and Environmental Medicine. 63(10). e694–e700. 2 indexed citations

Wong, Karrie, Sharon Lin, Isabelle Le Mercier, et al.. (2021). 204 KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors. Regular and Young Investigator Award Abstracts. A215–A215. 3 indexed citations

Wong, Karrie, Sharon Lin, Leila J. Williams, et al.. (2021). 186 Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1. SHILAP Revista de lepidopterología. A198–A198. 1 indexed citations

Lavin, Robert A., et al.. (2020). Gabapentinoid and Opioid Utilization and Cost Trends Among Injured Workers. Journal of Occupational and Environmental Medicine. 63(2). e46–e52. 3 indexed citations

Williams, Leila J., Courtney W. Hudgens, Grant M. Fischer, et al.. (2020). The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies. Molecular Cancer Therapeutics. 20(3). 500–511. 112 indexed citations

10.

Bernacki, Edward J., et al.. (2020). What Industrial Categories Are Workers at Excess Risk of Filing a COVID-19 Workers’ Compensation Claim? A Study Conducted in 11 Midwestern US States. Journal of Occupational and Environmental Medicine. 63(5). 374–380. 11 indexed citations

11.

Stevens, Sarah, et al.. (2020). Precision Antifungal Treatment Significantly Extends Voice Prosthesis Lifespan in Patients Following Total Laryngectomy. Frontiers in Microbiology. 11. 975–975. 7 indexed citations

12.

Prasad, Rishika, et al.. (2020). Abstract PR06: The glutaminase inhibitor CB-839 potentiates antimelanoma activity of standard-of-care targeted therapies and immunotherapies. Cancer Research. 80(19_Supplement). PR06–PR06. 1 indexed citations

13.

Peng, Weiyi, Leila J. Williams, Chunyu Xu, et al.. (2019). Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma. Clinical Cancer Research. 25(21). 6406–6416. 33 indexed citations

14.

Huang, Lu, Zibo Chen, Leila J. Williams, et al.. (2019). Abstract 3279: All-trans-retinoic acid (ATRA) markedly augments anti-tumor immunity. Cancer Research. 79(13_Supplement). 3279–3279. 1 indexed citations

15.

Cascone, Tina, Haïfa Hamdi, Fahao Zhang, et al.. (2018). Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Research. 78(13_Supplement). 1719–1719. 33 indexed citations

16.

Peng, Weiyi, Chunyu Xu, Brenda Melendez, et al.. (2018). Abstract 4938: OX40 agonist antibody-based combination therapy with PI3Kβ selective inhibitor enhances T cell immunity. Cancer Research. 78(13_Supplement). 4938–4938. 2 indexed citations

17.

Kettler, Ryan J., Stephen N. Elliott, Alexander Kurz, et al.. (2013). Predicting End-of-Year Achievement Test Performance. Assessment for Effective Intervention. 39(3). 156–169. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact